Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Seth Klarman’s Biotech Stock Picks

Next in line is Keryx Biopharmaceuticals (NASDAQ:KERX), in which Baupost disclosed holding 18.30 million shares valued at $258.95 million. The stock inched up by 2% during 2014 and Mr. Klarman after initiating a stake with 6.31 million shares during the first quarter has been raising his exposure to the stock throughout the next six months. Keryx Biopharmaceuticals (NASDAQ:KERX) is focused on developing therapies for patients with renal diseases. Earlier this year, three analysts lowered their price targets on the stock, although the consensus rating is still ‘Buy’. Stifel Nicolaus reduced its price target to $19.00 from $22.00, while Roth Capital and Mizuho decreased their price targets to $27.00 and $25.00 respectively; all three analysts have ‘Buy’ ratings on the stock. Another investor bullish on Keryx Biopharmaceuticals (NASDAQ:KERX) is healthcare hedge fund Deerfield Management, led by James E. Flynn, which owns 1.18 million shares as of the end of 2014.

Forward Pharma A/S (NASDAQ:FWP) represents a new position in Baupost Group’s equity portfolio as the fund revealed an $111.80 million position that contains 5.37 million shares. The company went public in October and its stock appreciated by 33% since the IPO. Forward Pharma A/S (NASDAQ:FWP)  is currently engaged in the development of a drug used for the treatment of multiple sclerosis and other immune disorders. The company is currently working on Phase 3 clinical trial using FP187, a proprietary formulation of dimethyl fumarate. Another hedge fund that disclosed a stake as Forward Pharma went public is Peter Kolchinsky’s RA Capital Management, which owns 970,600 shares as of the end of 2014.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...